(P067) The Role of Offline PET-CT Imaging in Evaluating the Particle Beam Range and Beam Stop for Prostate Cancer Treated With Heavy Ion Therapy

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Posttreatment offline PET-CT imaging has the potential to evaluate the particle beam range and beam stop for prostate cancer patients treated with heavy ion therapy, which might overcome the pitfalls of simple bone structure fusions with two-dimensional imaging, and provides another approach to monitor the treatment accuracy of prostate cancer treated with carbon ion therapy. Further investigation needs to be performed.

Qing Zhang, Jingyi Cheng, Jiandong Zhao, Xiaomeng Zhang, Xin Cai, Jin Meng, Shen Fu; Shanghai Proton and Heavy Ion Center; Fudan University Shanghai Cancer Center; Shanghai Jiao Tong University, Shanghai No. 6 People’s Hospital; Shanghai Proton and Heavy Ion Center/Fudan University Shanghai Cancer Center

PURPOSE: To evaluate the possibility of offline positron emission tomography-computed tomography (PET-CT) in monitoring both particle beam range and beam stop after carbon ion therapy.

MATERIALS AND METHODS: From June 2014 to September 2014, a total of 19 patients with pathology-confirmed primary prostate adenocarcinoma underwent carbon ion therapy in Shanghai Proton and Heavy Ion Center. All patients received a PET-CT scan shortly after carbon ion therapy. We divided these patients into two groups; 3 of 19 patients were treated with a single lateral beam in the first 4 days of carbon ion therapy, followed by a bilateral beam from day (D) 5, and PET-CT images were collected on D1, D4, D11, and the last day of the treatment. Another 16 patients were treated with bilateral beam only, and PET-CT imaging was collected on D1, D4/5, and the last day of the treatment. After irradiation, patients were transferred immediately to the PET-CT room nearby the irradiation center. A PET-CT scan was done on a Siemens Biograph mCT 5–7 minutes after carbon ion therapy, with no additional radioactive tracer injection. PET-CT images were collected for approximately 30 minutes for each patient, while the patient’s position during the PET-CT scan was the same as during treatment using the same immobilization device. Finally, a total of 60 PET-CT images were investigated. PET-CT and planning CT were further registered by matching the pelvic bones. An additional comparison with the expected β+ activity distribution was performed to identify either beam range or beam stop with accurate anatomical coregistration.

RESULTS: Based on the different tissue densities, we found different activation effects shown on PET imaging, such as skin, bone, fat, and prostate. Compared with the diagnostic CT, the measured activity with different anatomic structures was correlated, which indicated an accurate beam range. For the three patients treated with single-beam irradiation, the PET imaging also indicated the beam stop well. Our data further showed that the PET-CT–defined beam range covered the clinical target volume well, especially for the isocenter, by matching the PET-CT imaging with treatment planning.

CONCLUSION: Posttreatment offline PET-CT imaging has the potential to evaluate the particle beam range and beam stop for prostate cancer patients treated with heavy ion therapy, which might overcome the pitfalls of simple bone structure fusions with two-dimensional imaging, and provides another approach to monitor the treatment accuracy of prostate cancer treated with carbon ion therapy. Further investigation needs to be performed.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content